Role of recovery of acetylcholine release in compromised neuromuscular junction function.

Compromised neuromuscular transmission Fatigability Muscle weakness Recovery of acetylcholine release Repetitive nerve stimulation

Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
24 Jan 2024
Historique:
received: 25 09 2023
revised: 17 12 2023
accepted: 22 01 2024
medline: 16 2 2024
pubmed: 16 2 2024
entrez: 15 2 2024
Statut: aheadofprint

Résumé

Everyday physical activities, such as walking, are enabled by repeated skeletal muscle contractions and require a well-functioning neuromuscular transmission. In myasthenic disorders, activities of daily living are debilitated by a compromised neuromuscular transmission leading to muscle weakness and fatiguability in patients. To enable physical activity, acetylcholine (ACh) is released repeatedly from the motor nerve, however, the role of the nerve terminals' capacity to sustain ACh release to support repetitive contractions under compromised neuromuscular transmission remains unclear. To explore this, we studied synaptic and contractile function during repeated contractions in healthy rat skeletal muscles under conditions of pharmacological induced compromised neuromuscular transmission. Using recordings of endplate potentials, compound muscle action potential (CMAP) and force production in isolated skeletal muscles and living, anesthetized animals, we found that force and CMAP were markedly reduced by even very light activity performed up to 5 s prior to contraction showing that recovery of ACh release was insufficient to maintain synaptic transmission strength. Our results suggest that the timing of depletion and restoration of ACh release may impact clinical signs of weakness and fatigability in patients with impaired neuromuscular transmission and affect the sensitivity of electromyographic recordings in the clinic.

Identifiants

pubmed: 38359767
pii: S0960-8966(24)00036-1
doi: 10.1016/j.nmd.2024.01.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-59

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jeppe Blichfeldt Winther (JB)

NMD Pharma A/S, Palle Juul-Jensens Blvd. 82, 8200 Aarhus N, Denmark.

Jeanette Jeppesen Morgen (JJ)

NMD Pharma A/S, Palle Juul-Jensens Blvd. 82, 8200 Aarhus N, Denmark.

Martin Skov (M)

NMD Pharma A/S, Palle Juul-Jensens Blvd. 82, 8200 Aarhus N, Denmark.

Martin Gruwier Broch-Lips (MG)

NMD Pharma A/S, Palle Juul-Jensens Blvd. 82, 8200 Aarhus N, Denmark.

Ole Bækgaard Nielsen (OB)

Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark.

Kristian Overgaard (K)

Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark.

Thomas Holm Pedersen (TH)

NMD Pharma A/S, Palle Juul-Jensens Blvd. 82, 8200 Aarhus N, Denmark; Department of Biomedicine, Aarhus University, Ole Worms Allé 4, 8000 Aarhus C, Denmark. Electronic address: thp@biomed.au.dk.

Classifications MeSH